ライフサイエンスコーパス: epoxomicin

1 binding mode similar to the natural product epoxomicin.

2 ST motif, or via proteasomal inhibition with epoxomicin.

3 pe generation is enhanced in the presence of epoxomicin.

4 teasome-specific inhibitors, lactacystin and epoxomicin.

5 he inhibitors MG115, MG132, lactacystin, and epoxomicin.

6 Treatment of cells with epoxomicin (a proteasomal inhibitor) led to a dramatic i

7 Epoxomicin, a potent and selective inhibitor of the 20S

8 in Tg-CAPKN mice was partially inhibited by epoxomicin, a proteasome inhibitor.

9 The proteasome inhibitor epoxomicin abolished the MyD88 degradation induced by TG

10 Epoxomicin also effectively inhibits NF-kappaB activatio

11 K inhibitor (U0126) or proteasome inhibitor (epoxomicin) also up-regulated Bim accumulation and rende

12 alues for the specific proteasome inhibitors epoxomicin and bortezomib for each of the catalytic site

13 The proteasome inhibitors epoxomicin and MG132 significantly abrogated degradation

14 temically to mice, the proteasome inhibitors epoxomicin and proteasome inhibitor-1 increased bone vol

15 ces of the proteasome inhibitors bortezomib, epoxomicin, and Cbz-Leu(3)-aldehyde.

16 (1)-ATZ was inhibited by lactacystin, MG132, epoxomicin, and clasto-lactacystin beta-lactone.

17 cells to proteasome inhibitors (bortezomib, epoxomicin, and MG132), but not to proteotoxic or ER str

18 Utilizing biotinylated-epoxomicin as a molecular probe, we demonstrate that epo

19 These results thus define epoxomicin as a novel proteasome inhibitor that likely w

20 The proteasome inhibitors, lactacystin and epoxomicin, attenuated MIP-1beta induced CCR5 down-modul

21 wed that the proteasome inhibitors MG132 and epoxomicin blocked a postentry step in vaccinia virus (V

22 roteasome inhibitors MG132, lactacystin, and epoxomicin blocked PICT1 degradation, whereas the inhibi

23 lthough addition of the proteasome inhibitor epoxomicin blocked the presentation of two epitopes, pre

24 In contrast, the proteasome inhibitor epoxomicin caused a decrease in the levels of many of th

25 In that model, the proteasome inhibitor epoxomicin completely prevented LVH while blocking prote

26 fic inhibitors, lactacystin-beta-lactone and epoxomicin, could not stabilize HNE-modified proteins in

27 in as a molecular probe, we demonstrate that epoxomicin covalently binds to the LMP7, X, MECL1, and Z

28 d proteins in rat cortical neurons, although epoxomicin did.

29 t to peptide aldehyde proteasome inhibitors, epoxomicin does not inhibit nonproteasomal proteases suc

30 requirement for proteasomal processing of an epoxomicin-enhanced epitope, an in vitro proteasome dige

31 nfirm that both the epoxomicin-inhibited and epoxomicin-enhanced epitopes are processed cytosolically

32 Three closely related analogues of epoxomicin have been synthesized.

33 The efficacy of epoxomicin in restoring function suggests that protease

34 ystin and the specific proteasomal inhibitor epoxomicin increased soluble protein levels of the poly(

35 G1 is stabilized by the inhibitors MG132 and epoxomicin, indicating that it is degraded by the 26S pr

36 To further confirm that both the epoxomicin-inhibited and epoxomicin-enhanced epitopes ar

37 In addition, epoxomicin is a more potent inhibitor of the chymotrypsi

38 synthesis of the potent proteasome inhibitor epoxomicin, is described.

39 esting that some other protein(s) induced by epoxomicin may regulate poly(Q) aggregation.

40 urs in the presence of proteasome inhibitors epoxomicin or bortezomib.

41 y injected six doses of naturally occurring (epoxomicin) or synthetic (Z-lle-Glu(OtBu)-Ala-Leu-al [PS

42 ed bovine erythrocyte proteasome reveal that epoxomicin potently inhibits primarily the chymotrypsin-

43 The proteasome inhibitor epoxomicin raised ubiquitinated protein levels at least

44 bitors PSI (Z-Ileu-Glu(OtBu)-Ala-Leu-CHO) or epoxomicin recapitulated many of the degenerative change

45 e therefore evaluated a novel, irreversible, epoxomicin-related proteasome inhibitor, carfilzomib.

46 ith the proteasome inhibitors lactacystin or epoxomicin reversed m155 down-regulation of H60.

47 With epoxomicin, soluble p62/SQSTM1 associated with proteasom

48 ow that the potent antitumor natural product epoxomicin specifically targets the proteasome.

49 ect was reversed by the proteasome inhibitor epoxomicin, suggesting a Sir2alpha-mediated ubiquitin/pr

50 PC12 cell model, aggregation was reduced by epoxomicin, suggesting that some other protein(s) induce

51 binding of the proteasome-specific inhibitor epoxomicin to BPH.

52 Furthermore, administration of PSI or epoxomicin to monkeys in an attempt to extend the model

53 Epoxomicin treatment also rescued intercellular transfer

54 nce it is prevented by either lactacystin or epoxomicin, two inhibitors of proteasomal degradation.

55 , and by the proteasome inhibitors MG132 and epoxomicin, which prolong GHR signaling to STAT5b.

56 replication was inhibited by both MG132 and epoxomicin, which would account for the effect on interm